PBH catalyst calendar

Prestige Consumer Healthcare Inc.

Upcoming catalysts
2
Cash runway
Cash generating
Cash & investments
$89M
Phase 3 programs
2

Prestige Consumer Healthcare Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Prestige Consumer Healthcare Inc. generates cash from operations, so a burn-based runway figure does not apply.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
June 15, 2027 To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects Trial Milestone Phase 1

Track PBH alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PBH in the tracker

Recent history

DateEventTypePhase
August 14, 2026 8-K filed: Leadership change Corporate —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 15, 2026 8-K filed: Material agreement Corporate —
July 15, 2026 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer Trial Milestone Phase 1/Phase 2
July 6, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 16, 2026 8-K filed: Material agreement, Acquisition completed, Other event Corporate —
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 20, 2026 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
February 5, 2026 Quarterly results filed (8-K) Earnings —
November 6, 2025 Quarterly results filed (8-K) Earnings —
August 7, 2025 Quarterly results filed (8-K) Earnings —
May 8, 2025 Quarterly results filed (8-K) Earnings —
July 1, 2024 A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients Trial Milestone Phase 3
August 19, 2019 A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects Trial Milestone Phase 1
April 19, 2019 A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients Trial Milestone Phase 3
March 13, 2019 To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.